TRx-237-007 Phase 3 clinical trial fails to achieve its coprimary endpoints.

ABERDEEN, Scotland and Singapore, 4th September 2016 – TauRx Therapeutics Ltd today announced that its TRx-237-007 Phase 3 clinical trial of the company’s second generation tau aggregation inhibitor, LMTX®, in 220 subjects with behavioural variant frontotemporal dementia (bvFTD) failed to achieve its coprimary endpoints. The TRx-237-007 Phase 3 clinical trial, believed to be the largest randomized clinical study ever undertaken in this patient population, adds to the scarce scientific evidence and understanding of this rare condition. Its outcomes and findings will hopefully lead towards therapeutic solutions for these patients in the future.

Read more here.